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This review discusses recent data on immune signaling
pathways involved in the pathogenesis of colitis-associated
cancer. These include molecular mechanisms activating the
innate and adaptive immune system and thereby contrib-
uting to cancer initiation and promotion in inﬂammatory
bowel diseases.
The inﬂammatory bowel diseases ulcerative colitis and
Crohn’s disease are associatedwith an increased risk for the
development of colorectal cancer. During recent years,
several immune signaling pathways have been linked to
colitis-associated cancer (CAC), largely owing to the avail-
ability of suitable preclinical models. Among these, chronic
intestinal inﬂammation has been shown to support tumor
initiation through oxidative stress–induced mutations.
A proinﬂammatory microenvironment that develops,
possibly as a result of defective intestinal barrier function
and host–microbial interactions, enables tumor promotion.
Several molecular pathways such as tumor necrosis factor/
nuclear factor-kB or interleukin 6/signal transducer and
activator of transcription 3 signaling have been identiﬁed as
important contributors to CAC development and could be
promising therapeutic targets for the prevention and
treatment of CAC. (Cell Mol Gastroenterol Hepatol
2015;1:6–16; http://dx.doi.org/10.1016/j.jcmgh.2014.11.006)
Keywords: Colorectal Cancer; Crohn’s Disease; Cytokines;
Inﬂammatory Bowel Disease; Interleukin-6; Tumor Necrosis
Factor Alpha; Ulcerative Colitis.
oncepts about inﬂammation-associated cancerAbbreviations used in this paper: AOM-DSS, azoxymethane–dextran
sulfate sodium; APC, adenomatous polyposis coli; CAC, colitis-
associated cancer; CD, Crohn’s disease; CRC, colorectal cancer;
DDR, DNA damage response; gp, glycoprotein; IBD, inﬂammatory
bowel disease; IKK, IkB kinase; IL, interleukin; IL6R, interleukin 6 re-
ceptor; LPS, lipopolysaccharide; Myd88, myeloid differentiation pri-
mary response gene 88; NF-kB, nuclear factor-kB; NLR, NOD- and
leucine-rich repeat–containing protein; NLRP, nucleotide-binding
oligomerization domain- and leucine-rich repeat–containing protein
family, pyrin domain-containing; NOD, nucleotide-binding oligomeri-
zation domain; RONS, reactive oxygen and nitrogen species; STAT3,
signal transducer and activator of transcription 3; Th17, T-helper 17;
TLR, Toll-like receptor; TNF, tumor necrosis factor; TNFR, tumor ne-
crosis factor receptor; UC, ulcerative colitis.
© 2015 The Authors. Published by Elsevier Inc. on behalf of the AGA
Institute. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
2352-345X
http://dx.doi.org/10.1016/j.jcmgh.2014.11.006Cdevelopment go back to Rudolph Virchow’s obser-
vation of increased immune cell inﬁltration at tumor sites
more than 150 years ago.1 Today, inﬂammatory conditions
including infection and immune-mediated disease increase
the risk of cancer. Well-known examples in the gastroin-
testinal tract are the increased risk for gastric cancer and
gastric lymphoma in Helicobacter pylori infection and the
increased risk for colorectal cancer (CRC) in inﬂammatory
bowel disease (IBD).2
The ﬁrst reports of colorectal cancer in IBD patients
occurred in the early 1900s, when Crohn and Rosenberg3
described a case of colonic adenocarcinoma in a patient
with long-term ulcerative colitis (UC). The CRC risk in IBD
patients initially was attributed mostly to UC and not to
Crohn’s disease (CD) because epidemiologic studies in the
1960s had proposed an up to 10 times greater CRC risk inUC, but not in CD, patients in comparison with the general
population.4 Disease extent and duration are regarded as
the most important parameters affecting the individual CRC
risk in patients with UC. Recent data also have shown an
association between the degree of inﬂammation and the
development of colonic neoplasia.5,6 Additional risk factors
include primary sclerosing cholangitis and a family history
of CRC.7 Together, the cumulative risk for CRC in UC pa-
tients has been reported as 1.6% after 10 years, 8.3% after
20 years, and 18.4% after 30 years of disease duration.8
Because these data are based on studies from academic
centers, which frequently have patients with more severe
disease, true incidence rates may be lower. For instance,
Jess et al9 reported a 2.4-fold increased risk for CRC in UC
patients after 15 years of disease in a meta-analysis of
population-based cohort studies.
In contrast to UC, the inﬂuence of CD on CRC risk has
been under debate for many decades. Although several
cases of CRC were reported in CD patients beginning in the
1950s, subsequent studies could not detect increased inci-
dence rates in comparison with the general population.10
Recent studies have reported that the risk for CRC in pa-
tients with CD patients depends on large-bowel involve-
ment. Similar to UC, the extent and duration of colonic
inﬂammation are the most important risk factors for CRC
development in CD patients. In this regard, the cumulative
risk for CRC in CD patients has been reported to be 2.9%,
5.6%, and 8.3% after 10, 20, and 30 years of disease,
respectively, in a meta-analysis.11 Again, these data are
based on studies from academic centers and therefore may
overstate the actual incidence rates in patients with CD.
Because of the availability of reasonable preclinical
models, our knowledge regarding the molecular mecha-
nisms connecting inﬂammation and cancer development in
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recent years. Chronic inﬂammation has been linked to tu-
mor initiation, in which normal cells acquire genomic al-
terations that initiate tumorigenesis, as well as promotion
driven by the sustained proliferation of initiated cells.12 This
review discusses recent progress in understanding immune
signaling pathways involved in these steps during colitis-
associated cancer development.
Oxidative Stress–Induced DNA
Damage in CAC
For tumor initiation, distinct mutations of oncogenes or
tumor-suppressor genes are required to allow subsequent
tumor development. These include mutations that result in
resistance to apoptosis as well as acquisition of malignant
potential. Mutations involved in the initiation of sporadic
colorectal carcinoma have been well characterized and
accumulate along the individual steps of described
adenoma–carcinoma sequence pathways.13,14 Similarly, a
sequence of distinct mutations occurs during the stepwise
development of colitis-associated cancer. This can be referred
to as the inﬂammation–dysplasia–carcinoma pathway, which
describes the development of low-grade dysplasia in a
background of intestinal inﬂammation, with subsequent
progression to high-grade dysplasia, and, ﬁnally, invasive
carcinoma.15 Notably, not all lesions follow this stepwise
evolution. Because the tumorigenic pathway and individual
genes affected differ between sporadic and colitis-associated
CRC, it is reasonable to propose that the mechanisms
inducing these mutations also differ. Mutations in sporadic
CRC have been attributed to several kinds of genomic and
epigenetic instability including chromosomal instability, CpG
island methylator phenotype, global hypomethylation, and
mutations in mismatch repair genes that lead to microsatel-
lite instability.16 Although these genomic and epigenetic
alterations also occur in CAC,17 growing evidence supports
a central role for inﬂammation-dependent oxidative stress
in the induction of mutations that lead to CAC.
Oxidative stress occurs as an imbalance of the genera-
tion and elimination of reactive oxygen and nitrogen spe-
cies (RONS).18 Increased oxidative stress is one of the key
features of chronic inﬂammation because cells of the innate
immune system release various kinds of RONS including
superoxide, hydrogen peroxide, singlet oxygen, hydroxyl
radicals, and nitric oxide into the tissue microenvironment
on activation. These RONS interact with the DNA of resident
cells and induce various forms of DNA damage including
single- and double-strand breaks, abasic sites, and nucleo-
tide modiﬁcation, all of which contribute to tumor initiation
when they affect oncogenes or tumor-suppressor genes.19
In human IBD, studies have shown that increased RONS
correlates with disease activity, as well as reduced antioxi-
dant levels. For instance, 8-oxo-7,8-dihydro-2,-deoxy-
guanosine, an oxidative stress–dependent base modiﬁcation,
is common in inﬂamed and dysplastic tissue, but not in
healthy mucosa.20 Similarly, concentrations of nitric oxide
are increased and correlate with oxidative damage in tissue
samples of active and even inactive IBD.21To repair reactive oxygen species-induced mutations, the
DNA damage response (DDR) is activated, which comprises
various mechanisms including direct repair, nucleotide
excision repair, and others (see the article by Curtin22 for a
review). Furthermore, the DDR can regulate cellular prolif-
eration through activation of premature cellular senescence,
an irreversible arrest of cell-cycle progression that protects
against the ampliﬁcation of defective DNA and proliferation
of mutant clones.23 Senescence occurs in various precan-
cerous lesions, and evasion as a result of mutations in
senescence-associated genes has been regarded as a
requirement for malignant transformation.
In IBD, Sohn et al24 found an increase of DDR (Histon
gamma H2A.X, phospho-checkpoint kinase 2) and senes-
cence (Heterochromatin protein 1 gamma) markers in
inﬂamed tissue samples from IBD patients. In UC samples,
increased DDR and senescence correlated with inﬁltration
of macrophages as a possible source of RONS. Supporting
the activation of senescence as a protective mechanism
against malignant transformation in CAC, high levels of
senescence markers have been reported in low-grade
dysplasia in comparison with nondysplastic inﬂamed tis-
sues and also high-grade dysplasia of UC patients, proposing
an evasion of senescence during the progression from low-
to high-grade dysplasia.25,26
Evidence for the pathogenic role of oxidative stress and
protection afforded by the DDR is provided by preclinical
studies using CAC models. Meira et al27 showed that mice
deﬁcient in alkyladenine DNA glycosylase, an enzyme
involved in base excision repair, developed more DNA base
lesions and higher numbers of tumors in the widely used
azoxymethane–dextran sodium sulfate (AOM-DSS) model of
CAC. In the same model, mice deﬁcient in the transcription
factor nuclear factor-erythroid 2–related factor 2, which
regulates genes involved in antioxidant signaling pathways,
also had increased numbers of aberrant crypt foci.28
Furthermore, mice lacking the glutathione peroxidase
Glutathione peroxidase 3, which is regulated by nuclear
factor-erythroid 2–related factor 2 and acts as a redox
enzyme, develop more tumors with higher grades of
dysplasia in the AOM-DSS model.29 GPX3-deﬁcient mice
even developed polyps after DSS treatment without AOM,
indicating that increased oxidative stress without an effec-
tive DDR is sufﬁcient for tumor initiation. After tumor
initiation, the proinﬂammatory microenvironment also
contributes to tumor promotion.
Proinﬂammatory Signaling Pathways:
The Role of Nuclear Factor-kB in Tumor
Initiation and Promotion
Inﬂammation occurring as a response to infection or
tissue damage removes dead cells and promotes restoration
of tissue integrity via stem cell and myoﬁbroblast activation,
cell proliferation, angiogenesis, and other processes.
Because of the overlap between mechanisms involved in
wound healing and tumorigenesis, tumors have been
described as “wounds that do not heal.”30 In fact, chronic
inﬂammation can result in excessive tissue regeneration and
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tumor cells.31 During recent years, major proinﬂammatory
pathways have been implicated in inﬂammation-associated
tumor development. Among these, the group of nuclear
factor-kB (NF-kB) transcription factors takes center stage.
NF-kB transcription factors comprise dimers of the subunits
RelA (p65), c-Rel, RelB, p50/NF-kB1, and p52/NF-kB2.32 In
a resting state, NF-kB dimers are bound to speciﬁc inhibitors
(Ik) within the cytoplasm. Two signaling pathways leading
to NF-kB activation have been reported. In the classic
pathway, proinﬂammatory stimuli including tumor necrosis
factor a (TNFa), interleukin 1 (IL1), lipopolysaccharide
(LPS), and CD40 ligand lead to activation of the IkB kinase
(IKK) subunits IKK-a, IKK-b, and IKK-g (NF-kappa-B
essential modulator), which together target IkB proteins for
proteosomal degradation. Subsequently, unbound NF-kB
dimers (primarily RelA/p50) translocate to the nucleus and
initiate transcription of target genes. The alternative
pathway largely is dependent on activation by lymphotoxin
a/b and CD40L, but not TNFa, IL1, or LPS. Alternative
pathway activation leads to the conversion of p100 to p52
via IKK-a–dependent phosphorylation and subsequent
proteosomal cleavage. The resulting p52/RelB heterodimers
translocate to the nucleus and lead to target gene tran-
scription (for review see the article by Karin et al33). Both
pathways of NF-kB activation lead to increased expression
of genes involved in the regulation of cell-cycle progression,
apoptosis, and other cancer-relevant signaling pathways.
In CAC, the initial evidence for the functional relevance
of NF-kB signaling was provided in a preclinical study by
Greten et al,34 which showed that deletion of IKK-b in in-
testinal epithelial cells resulted in decreased numbers of
tumors, increased apoptosis, and defective Bcl-Xl signaling.
In contrast, deletion of IKK-b in myeloid cells led to
diminished tumor size along with reduced expression of
proinﬂammatory cytokines including IL1b, TNFa, and IL6 in
the AOM-DSS model. These data suggest that tumor cell–
speciﬁc NF-kB activation is required for inﬂammation-
associated tumor initiation, and NF-kB activation in
myeloid cells contributes to tumor promotion and pro-
gression. In line with these data, mice with constitutive
activation of IKK-b in intestinal epithelial cells and germline
deletion of the tumor-suppressor gene adenomatous pol-
yposis coli (APC) show enhanced tumor development with
marked DNA damage and DDR activation.35 Because dif-
ferences in tumor load were largely dependent on tumor
numbers, and tumors even developed spontaneously in
mice with constitutively active IKK-b (even without APC
loss), these data again highlight the central roles of epithe-
lial NF-kB activation and oxidative stress in tumor initiation.
Interestingly, a study by Cooks et al36 found increased
NF-kB signaling in mice with a gain-of-function mutation of
TP53. The p53 protein generally acts as a mediator of
cellular senescence by triggering cell-cycle arrest. Mutations
affecting TP53 occur at late stages of sporadic CRC, usually
resulting in loss of p53 function, bypass of senescence, and
inﬁltrative and metastatic tumor growth.37,38 In contrast to
sporadic CRC, TP53 mutations occur at early steps of CAC,
before inﬁltrative or metastatic tumor growth. Therefore,the functional role of TP53 mutations at early steps of CAC
has been controversial. The data discussed earlier suggest
that gain-of-function mutations in TP53 at early steps of CAC
development enhance NF-kB signaling in tumor cells.36
Despite these advances, very few studies have analyzed
NF-kB signaling in human CAC.39,40
TNFa as a Link Between Chronic
Intestinal Inﬂammation and CAC
Because of its central role in maintaining chronic
inﬂammation in IBD, TNFa signaling has been proposed as a
tumor-promoting mechanism in CAC. The contribution of
TNFa to IBD is highlighted by the efﬁcacy of anti-TNFa
therapeutics that now routinely are used to treat IBD pa-
tients.41 TNFa, which is expressed as pro-TNF on the plasma
membrane of myeloid and T cells, is released after cleavage
by converting enzymes such as ADAM-17. Soluble TNFa
then binds to 1 of 2 receptors: TNF-Rp55 (TNFR1) or TNF-
Rp75 (TNFR2).41 Although activation of TNFR1 results in
apoptosis via caspase-3 activation, activation of TNFR2
promotes cell survival via activation of NF-kB and other
signaling pathways.42 Although TNF initially was discovered
and named as a factor that induces tumor necrosis, it now
has been implicated in the pathogenesis of inﬂammation-
associated cancer, likely as a consequence of proin-
ﬂammatory signaling. Functional evidence for this concept
has been provided by preclinical studies using the AOM-DSS
CAC model. TNFR2 expression is up-regulated on intestinal
epithelial cells in adoptive transfer and DSS colitis,43,44 and
increased NF-kB signaling after TNFR2 activation in the
AOM-DSS model.43 Treatment of mice with an anti-TNF
antibody reduced tumor number and size. TNFR2 activa-
tion in intestinal epithelial cells also leads to myosin light
chain kinase up-regulation with subsequent release of pro-
tumorigenic cytokines and breakdown of tight
junctions.44–46 Similar to TNFR2, tumor growth was
reduced in TNFR1-deﬁcient mice as well as in wild-type
mice treated with the anti-TNF inhibitor entanercept in
the AOM-DSS model.47 The effectiveness of entanercept is
somewhat surprising because this anti-TNF biologic is not
effective in human IBD. Nevertheless, reduced TNF signaling
is accompanied by decreased colonic inﬁltration by neu-
trophils and macrophages. Bone marrow chimera mice also
were used to show that the effects of TNFR1 on tumor
growth were caused by expression on bone
marrow–derived rather than stromal and parenchymal cell
types. Thus, TNFR1 activation in inﬁltrating immune cells
seems to be important for tumor-promoting effects of
chronic inﬂammation, whereas TNFR2 activation seems to
be important for NF-kB–dependent tumor cell survival, tight
junction barrier loss, and tumor-promoting cytokine release
(Figure 1).
Importantly, these data on TNF signaling in CAC were
derived from preclinical studies, whereas data from human
CAC are rare. Moreover, despite the widespread use of anti-
TNF therapeutics in IBD treatment, there are currently no
data available that clearly show a preventive effect on CAC
development.
Figure 1. TNFa-dependent activation of NF-kB in CAC.
TNF, a major proinﬂammatory cytokine involved in the path-
ogenesis of IBD, contributes to CAC development through
the activation of NF-kB in myeloid and intestinal epithelial
cells. Although TNFR1 activation in myeloid cells leads to
the release of additional proinﬂammatory cytokines that
contribute to tumor growth, TNFR2 activation in epithelial
cells promotes cell survival as well as the activation of myosin
light chain kinase (MLCK), which supports epithelial barrier
loss through direct effects on tight junctions (TJ). After TNFR2
activation, the MLCK promoter can be regulated via NF-kB or
activator protein 1. IEC, intestinal epithelial cell.
January 2015 Immune Signaling in CAC 9IL6-Dependent Signal Transducer
and Activator of Transcription 3
Activation in IECs
Another cytokine implicated in the pathogenesis of CAC
is IL6. On activation of proinﬂammatory signaling pathways
involving NF-kB or nuclear factor of activated T-cells, cyto-
plasmic 2, IL6 is released by monocytes, macrophages, ﬁ-
broblasts, endothelial cells, lymphocytes, and cancer cells.
This IL6 binds to membrane-bound IL6-receptor (IL6R) on
target cells, and the complex then binds to a homodimer of
glycoprotein 130 (gp130), which mediates further down-
stream signaling.48 In addition, IL6 can act on cells that do
not express IL6R. In this trans-signaling, IL6 binds to a
soluble form of IL6R and the complex binds to membrane-
bound gp130 on target cells to activate downstream
signaling. Initially, a role for IL6 in cancer development was
suggested by in vitro studies of growth-promoting effects on
colon cancer cell lines.49,50 Because these cells do notexpress membrane-bound IL6R, it was argued that IL6
signaling might act through trans-signaling.50 Evidence for
this concept was provided by Becker et al,51 who showed
that not only IL6R antibodies, but also sgp130Fc, a designer
protein that speciﬁcally blocks trans-signaling, limited tu-
mor development in the AOM-DSS model. Similar data
recently were provided by Matsumoto et al52 and Gri-
vennikov et al,53 who also found increased activation of
signal transducer and activator of transcription 3 (STAT3)
in tumor cells, suggesting that this transcription factor
contributes to increased tumor cell proliferation after IL6R
and Janus kinase activation. STAT3 induces target genes that
are important for tumor cell survival, proliferation, angio-
genesis, metastasis, cell adhesion, and inﬂammation.54 The
functional importance of STAT3 was emphasized by data
from Bollrath et al,55 who showed reduced tumor growth in
mice with a conditional deletion of STAT3 in intestinal
epithelial cells. Conversely, increased STAT3 activity in
gp130Y757F mice promoted tumor growth in the AOM-DSS
model.55 In that model, STAT3 activation resulted in
hyperproliferation of intestinal epithelial cells caused by
direct effects on regulators of G1 and G2/M transition.
Recent data from Brighenti et al56 also suggested that p53
down-regulation was induced by IL6 via increased proteo-
somal degradation. Rokavec et al57 recently studied mice
deﬁcient in miR-34a and found that they developed
increased numbers of tumors with increased STAT3 phos-
phorylation and invasive tumor growth partners in the
AOM-DSS model. This was caused by a feedback loop, in
which miR-34a inhibits IL6R expression and STAT3 inhibits
miR-34 expression. STAT3 activation also is necessary for
persistent NF-kB activation in tumor cells.58 This process is
mediated by STAT3-dependent nuclear retention of RelA,
which further ampliﬁes sustained transcription effects of
STAT3 and NF-kB, which are required for malignant
transformation.
A growing number of cytokines beyond IL6 now are being
recognized as activators of STAT3. For instance, a recent
study proposed a dominant role for IL11 in STAT3 activa-
tion, relative to IL6 in the AOM-DSS model, because IL11-
receptor a1–deﬁcient mice developed fewer tumors than
IL6-deﬁcient mice.59 Furthermore, autocrine vascular endo-
thelial growth factor signaling in intestinal epithelial cells can
promote STAT3 activation in AOM-DSS–treated mice.60
Although the relative importance of the individual mecha-
nisms leading to STAT3 activation remains to be deﬁned,
these preclinical data suggest that STAT3 may be a promising
therapeutic target for prevention of CAC (Figure 2).
Tumor-Promoting Effects of T-Helper
17 Cells
In addition to IL6 and TNF, proinﬂammatory cytokines
released by T-helper 17 (Th17) cells, which are important
for the adaptive immune response in IBD, have been
implicated in the pathogenesis of CAC. Th17 cells are a
heterogenous population of effector T cells characterized by
up-regulation of the transcription factor RAR-related orphan
receptor gT and release of proinﬂammatory cytokines
Figure 2. IL6- and IL11-dependent STAT3 activation pro-
motes tumor proliferation and survival. IL6 and IL11
released from immune cells such as macrophages and
effector T cells bind to their speciﬁc receptors and induce
STAT3 activation via gp130. Phosphorylated STAT3 pro-
motes survival and proliferation of intestinal epithelial cells via
direct effects on cell-cycle regulators (CC) and down-
regulation of p53. Furthermore, activated STAT3 promotes
sustained NF-kB activity. IL11R, IL11 receptor; sIL6R, soluble
IL6 receptor. IEC, intestinal epithelial cell.
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cells in tumor development initially was suggested by
Langowski et al,62 who showed that deﬁciency of IL23, a
member of the IL12 family of cytokines that contributes to
the differentiation of Th17 cells, led to increased tumor
resistance and decreased tissue inﬂammation in a cutaneous
tumor model. Consistent with this, anti-IL17A antibody
treatment of mice exposed to 1,2-dimethylhydralazine and
DSS also reduced tumor development.63 Furthermore, tu-
mor development in the AOM-DSS model was reduced in
IL17A-deﬁcient mice.64 Because this reduced tumor devel-
opment was accompanied by reduced intestinal inﬂamma-
tion with reduced levels of IL6, TNF, and other cytokines,
Th17 cells seem to mediate tumor development by
providing a proinﬂammatory microenvironment rather than
by direct effects on tumor cells. Similar data are available
for the Th17 family cytokine IL21. Stolﬁ et al65 analyzedIL21-deﬁcient mice in the AOM-DSS model and found
reduced tumor number and reduced expression of proin-
ﬂammatory cytokines, including IL6 relative to wild-type
mice. In contrast to the indirect effects of IL17A and IL21,
IL22 may signal directly to intestinal epithelial cells. For
example, IL22 leads to STAT3 activation in intestinal
epithelial cells during DSS-induced colitis and is required for
epithelial regeneration.66 Conversely, mice deﬁcient in the
IL22 binding protein, which acts as an IL22 scavenger, show
increased tumor growth in the AOM-DSS model owing to
increased epithelial IL22-dependent STAT3 activation.63
IL22, IL22-receptor a1, and IL23 expression all have been
shown to be increased in human UC and colon cancer
tissues.67,68
Overall, these data indicate that Th17 cells provide a
proinﬂammatory microenvironment that activates tumor-
promoting pathways. This concept is supported further by
data showing that mice with conditional deletion of APC in
colonial epithelial cells develop tumors in the distal colon,
but that crossing these mice with IL-23-deﬁcient, IL-23-
receptor-deﬁcient, or IL17A receptor–deﬁcient mice
reduced both tumor growth and expression of proin-
ﬂammatory cytokines, including IL6, IL17A, and IL22.69 Of
note, IL23 signaling was attributed mainly to the activation
of myeloid cells through the commensal microﬂora. Thus,
the authors of this article proposed a sequence in which
genetic defects lead to increased inﬁltration of tumor tissue
with microbial products and subsequent development of an
IL23/IL17-dependent inﬂammatory microenvironment that
leads to tumor promotion and progression. Although these
data were generated in a model of sporadic CRC, studies of
the role of microbiota and innate immune pathways in CAC
suggest that the conclusions are relevant to CAC.
Innate Immunity and the Microbiome
in CAC
Among the studies discussed earlier, Grivennikov et al69
attributed intestinal barrier loss to genetic alterations
occurring during sporadic CRC development. This may,
however, be relevant to CAC because increased intestinal
permeability has been linked to IBD pathogenesis.70–73
Although the mechanisms leading to intestinal barrier loss
and the relationship between this, host–microbial in-
teractions, and chronic innate and adaptive immune re-
sponses are not completely understood, barrier dysfunction
also may be important to the development of CAC. For
example, AOM administration to IL10-deﬁcient mice, which
spontaneously develop colitis, leads to tumor development
under normal conditions, but neither colitis nor tumorigen-
esis occur in IL10-deﬁcient mice housed under germ-free
conditions.74 Although some bacteria such as Helicobacter
hepaticus or Escherichia coli NC101 have been associated
with CAC development, a clear association of speciﬁc
microbiota with human CAC has not been identiﬁed.75,76
Although the factors leading to barrier defects in IBD still
are unknown, the resulting inﬂux of microbial products can
activate innate immunity, several pathways of which have
been implicated in CAC development. Among these, the
Figure 3. Microbiota and innate immune mechanisms
regulate a proinﬂammatory microenvironment promoting
tumor growth. Possibly as the result of a defective intestinal
barrier, microbial products activate innate immune cells or
intestinal epithelial cells (IECs), perhaps via TLRs, which then
create a proinﬂammatory microenvironment with subsequent
activation of Th17 cells characterized by the transcription
factor RAR-related orphan receptor gT (RORgt). Proin-
ﬂammatory cytokines released by activated innate immune
cells, intestinal epithelial cells, or Th17 cells contribute to
tumor cell proliferation and survival.
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attention because these receptors enable the detection of
pathogenic molecules and activate downstream pathways to
initiate a host immune response. Recent studies particularly
have implicated TLR4 signaling in the pathogenesis of CAC.
TLR4 is expressed by intestinal epithelial cells and various
cells of the immune system, and can be activated by LPS.77
Fukata et al78 showed that TLR4 is overexpressed in CAC
tissue of UC patients. Furthermore, TLR4-deﬁcient mice
were protected against CAC development in the AOM-DSS
model and had reduced myeloid cell inﬁltration and
cyclooxygenase-2 expression.78 These effects primarily
were owing to TLR4 signaling on colonic epithelial cells,
rather than myeloid cells, as shown in bone marrow
chimera experiments.79 In contrast, mice deﬁcient in TLR2
showed increased tumor development in the AOM-DSS
model.80 These effects have been attributed to a dysregu-
lated immune response after exposure to AOM-DSS rather
than direct effects on epithelial cells because TLR2-deﬁcient
mice had increased IL6 and IL17A expression.
Because signaling by TLR2 and TLR4 both are mediated
by the myeloid differentiation primary response gene 88
(Myd88), there is currently no explanation for the differ-
ences in tumor growth between TLR2- and TLR4-deﬁcient
mice. The situation is complicated further by the fact that
Myd88 either promotes or reduces tumor growth, depend-
ing on the CAC models used. For example, Myd88-deﬁcient
mice were more susceptible to AOM-DSS–induced tumors,
similar to the phenotype TLR2-deﬁcient, but not TLR4-
deﬁcient, mice.81 In contrast, Myd88 function is required
for inﬂammation-associated tumor development in
IL10–deﬁcient mice exposed to AOM and in wild-type mice
exposed to AOM and oxazolone.74,82 The mechanisms for
these differences in individual models and by the different
TLRs cannot be explained at a molecular level. The con-
ﬂicting data could be attributed to differences in microbiota
of mice with innate immune defects.83
Similar to TLRs, nucleotide-binding oligomerization
domain (NOD)- and leucine-rich repeat–containing proteins
(NLRs) have been implicated in the pathogenesis of IBD and
CAC. For example, mutations of the CARD15 gene encoding
NOD2 have been associated with Crohn’s disease.73,84 NOD2
deﬁciency leads to dysbiosis with increased intestinal
inﬂammation that promotes tumor development after AOM
injection.85 CAC risk was transmitted by transferring fecal
microbiota from NOD2-deﬁcient mice to wild-type mice,
suggesting that NOD2 effects were caused primarily by
effects on microbial communities.
Another downstream mechanism after NLR activation is
activation of the inﬂammasome, a multiprotein complex
containing NLR family, pyrin domain-containing (NLRP)
proteins NLRC4 and NAIP.70 This complex leads to the
activation of caspase-1, which cleaves pro-IL1b and pro-
IL18 to facilitate release of these proinﬂammatory cyto-
kines. Interestingly, mice lacking the NLRP3 component of
the inﬂammasome show more tumor development in the
AOM-DSS model, suggesting a protective role for inﬂam-
masome activation in CAC.86 Data were similar for NLRP6
and NLRP12.87–90 Together, the results suggest that the hostresponse to intestinal microbiota can lead to both tumor-
promoting or tumor-inhibiting effects (Figure 3). We hope
that the growing body of literature regarding these mech-
anisms will allow future growth in understanding individual
contributions of these and other mechanisms to human CAC.Conclusions
During recent decades, our knowledge of the molecular
mechanisms involved in the development of colitis-
associated cancer has improved dramatically. In addition
to the tumor-initiating effects of oxidative stress, several
regulatory pathways, including TNF/NF-kB and IL6/STAT3
signaling, have been identiﬁed that are important mediators
of tumor promotion and progression. Parallel efforts to
determine the pathogenesis of IBD and roles of
host–microbial interactions have led to the conclusion that
many of these also are modulators of intestinal tumor
development (Table 1 shows a summary of the anticipated
mechanisms). Despite these advances, not all data acquired
in preclinical models can be translated to human disease.
Table 1. Immune Signaling Pathways Involved in the Development of CAC
Pathway Molecule Function Preclinical data Evidence in human disease References
OS 8-OH-dG Marker for OS Increased 8-OH-dG in
inﬂamed and dysplastic
tissue samples of UC
patients
20
NO Marker for OS Increased NO concentrations
in active and inactive IBD
21
DDR gH2A.X Marker for DDR activation Increased in IBD tissue 24
Aag Enzyme involved in base
excision repair
Aag deﬁciency: increased number of DNA base
lesions and tumors in the AOM-DSS model
27
Nrf2 Transcription factor involved
in the regulation of redox
mechanisms
Nrf2 deﬁciency: Increased number of tumors in the
AOM-DSS model
28
Glutathione
peroxidase
GPX3
Redox enzyme GPX3 deﬁciency: increased tumors in the AOM-
DSS model, even tumor development after DSS
treatment without AOM
29
TNFa/NF-
kB signaling
NF-kB Proinﬂammatory transcription
factor
Deletion of IKK-b in myeloid cells: reduced tumor
size and deletion of IKK-b in intestinal epithelial
cells decreased tumor number in AOM-DSS
model.
Overexpression of constitutively active IKK-b in
APC-deﬁcient mice increased tumor
development, DNA damage, and DDR
Increased activity of NF-kB in
IBD tissue, no evidence in
human CAC
34, 35, 39, 40
TNF2 Proinﬂammatory cytokine
involved in NF-kB activation
Anti-TNFa treatment protective in AOM-DSS
model, TNFR1 signaling in myeloid cells
promotes proinﬂammatory microenvironment,
TNFR2 signaling in intestinal epithelial cells
promotes tumor cell survival
Increased TNFa signaling and
anti-TNF therapy in IBD
patients. No distinct proof
for functional role of TNFa
in human CAC
45, 47, 50
IL6/IL11/
STAT3
signaling
IL6 Proinﬂammatory cytokine Mice with deﬁcient IL6 signaling or treatment with
anti-IL6 antibodies reduces tumor growth in
AOM-DSS model
IL6 promotes growth of human
colorectal cancer cell lines
51–54, 91
IL11 Proinﬂammatory cytokine,
member of IL6 family
IL11-receptor a1 deﬁciency: protection against
tumor development in the AOM-DSS model
60
STAT3 Transcription factor mediating
effects of IL6-receptor
activation
Conditional deletion of STAT3 in intestinal
epithelial cells protects against, whereas
constitutive activation of STAT3 promotes
tumor development in the AOM-DSS model
56
miR-34 miR-34 induced by the tumor-
suppressor gene p53
miR-34 deﬁciency: increased IL6/STAT3 signaling
and tumor growth in the AOM-DSS model
58
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Table 1.Continued
Pathway Molecule Function Preclinical data Evidence in human disease References
Th17 cells IL17A Th17 effector cytokines Anti-IL17A antibody–treated and IL17A-deﬁcient
mice: protection in AOM-DSS model
64, 65
IL-21 IL21-deﬁcient mice: reduced tumor growth in
AOM-DSS model
66
IL-22 IL22 induces intestinal epithelial cell proliferation
via STAT3 activation. IL22 binding protein
deﬁciency promotes tumor growth in the
AOM-DSS model
Increased IL22 and IL22-
receptor expression in UC
and CRC tissue
67, 68, 92
TLR signaling TLR4 TLR activated by LPS TLR4 deﬁciency: reduced tumor growth in the
AOM-DSS model
Overexpressed in human CAC
tissue
79, 80
TLR2 TLR activated by bacterial cell
wall components
TLR2 deﬁciency: increased tumor development in
AOM þ DSS model
81
Myd88 Downstream mediator of
TLR activation
Role of Myd88, depending on speciﬁc model.
Protective effect in AOM-DSS model; tumor-
promoting effect in IL10-deﬁcient mice treated
with AOM or wild-type mice treated with AOM
and oxazolone
75, 82, 93
Inﬂammasome/
NLR family
NLRP3 Inﬂammasome components NLRP3 deﬁciency: more tumors in the AOM-DSS
model
88
NLRP6 NLRP6 deﬁciency: increased intestinal
inﬂammation and tumor development in
AOM-DSS model
60, 87, 90
NLRP12 NLRP12 deﬁciency: increased NF-kB signaling
and tumor development
89
Aag, alkyladenine DNA glycosylase; 8-OH-dG, 8-oxo-7,8-dihydro-2,-deoxyguanosine; NO, nitric oxide; Nrf2, nuclear factor-erythroid 2–related factor 2; OS, oxidative stress.
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14 Waldner and Neurath Cellular and Molecular Gastroenterology and Hepatology Vol. 1, No. 1For instance, despite the involvement of TNF signaling in
CAC models, current clinical data do not show a distinct
reduction of CAC risk in IBD patients treated with anti-TNF
therapeutics. However, this information might become
available when there are more long-term data. Furthermore,
it will be important to see how new therapeutic strategies
targeting different molecular pathways, such as IL6 or
integrins, inﬂuence the development of CAC.References
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